Sun, Meili
Jinan Central Hospital · Shandong First Medical University
2 papers on CoChatORCID 0000-0002-4914-6508
Most cited papers
- Verified
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial
Zhou, C., Wang, Z., Sun, M., Cao, L., Ma, Z., Wu, R., Yu, Y., Yao, W., Sun, S., Chen, J., et al. (2025) · The Lancet Oncology
Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers
Cited by 23
- Verified
Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial
Shi, Y., Wu, L., Ji, Y., Chen, G., Li, B., Bi, M., Yang, R., Miao, L., Zhang, G., Gao, H., et al. (2025) · The Lancet Respiratory Medicine
Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment
Cited by 16
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free